AnteoTech Ltd. announced that it has been awarded up to $1.4 million towards the further development and commercialisation of its COVID-19 Antigen Rapid Test (ART)1, under the Queensland Government's Essential Goods and Supply Chain Program (EGSCP). AnteoTech will draw down up to $1.4 million against agreed milestones. The EGSCP program aims to help Queensland manufacturers make essential goods such as personal protective equipment, health consumables and devices, particularly in response to the COVID-19 pandemic. AnteoTech's submission focused on the development and commercialisation of its proposed 15-minute point of care COVID-19 Antigen Rapid Test (ART), harnessing AnteoTech's nanoparticle surface management technology AnteoBindTM and a Europium particle to provide high sensitivity fluorescent detection of the SARS-CoV-2antigen.